Telix Adds High-Profile Directors to Bolster Global Biopharma Push

Telix Pharmaceuticals ( (AU:TLX) ) just unveiled an announcement.

Telix Pharmaceuticals has expanded its board with the appointment of two additional non-executive directors, Maria Rivas and William Jellison, effective May 11, 2026, as part of a broader expansion and succession plan. Rivas brings extensive experience in late-stage clinical development and commercialization from senior roles at Pfizer and other healthcare firms, while Jellison adds deep corporate finance and audit committee expertise from his tenure as Stryker’s CFO and multiple U.S. board roles.

The company’s interim chair said the appointments, alongside the recent addition of David Gill, are designed to strengthen Telix’s governance, financial oversight and clinical leadership as it evolves as a dual-listed, global commercial-stage biopharmaceutical company. The bolstered board is expected to support Telix’s growing international footprint and sharpen its strategic positioning in the competitive radiopharmaceuticals market, potentially benefiting investors and other stakeholders through enhanced oversight and industry insight.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$31.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing radiopharmaceuticals to address significant unmet medical needs in oncology and rare diseases. Headquartered in Melbourne, it operates across North America, Europe, Brazil, Canada and Japan, and is dual-listed on the ASX and Nasdaq, reflecting its ambitions as a global commercial-stage player.

Average Trading Volume: 3,164,933

Technical Sentiment Signal: Hold

Current Market Cap: A$4.6B

Find detailed analytics on TLX stock on TipRanks’ Stock Analysis page.